Citations (30)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Xiaohong Xie, Shangyi Bao, Hong Zhao, Liuying Li & Xiaojun Fu. (2023) Efficacy and Safety of Bevacizumab for Treating Glioblastoma: A Systematic Review and Meta-Analysis of Phase II and III Randomized Controlled Trials. Cancer Investigation 41:3, pages 305-317.
Read now
Read now
Zhouqing Chen, Na Xu, Chongshun Zhao, Tao Xue, Xin Wu & Zhong Wang. (2018) Bevacizumab combined with chemotherapy vs single-agent therapy in recurrent glioblastoma: evidence from randomized controlled trials. Cancer Management and Research 10, pages 2193-2205.
Read now
Read now
Ulrik Lassen, Morten Mau-Sørensen & Hans Skovgaard Poulsen. (2014) Orphan drugs in glioblastoma multiforme: a review. Orphan Drugs: Research and Reviews 4, pages 83-91.
Read now
Read now
Hans Skovgaard Poulsen, Thomas Urup, Signe Regner Michaelsen, Mikkel Staberg, Mette Villingshøj & Ulrik Lassen. (2014) The impact of bevacizumab treatment on survival and quality of life in newly diagnosed glioblastoma patients. Cancer Management and Research 6, pages 373-387.
Read now
Read now
Articles from other publishers (26)
Elisa Checa-Chavarria, Eva Rivero-Buceta, Miguel Angel Sanchez Martos, Gema Martinez Navarrete, Cristina Soto-Sánchez, Pablo Botella & Eduardo Fernández. (2021) Development of a Prodrug of Camptothecin for Enhanced Treatment of Glioblastoma Multiforme. Molecular Pharmaceutics 18:4, pages 1558-1572.
Crossref
Crossref
Nathan McDannold, Yongzhi Zhang, Jeffrey G. Supko, Chanikarn Power, Tao Sun, Natalia Vykhodtseva, Alexandra J. Golby & David A. Reardon. (2020) Blood-brain barrier disruption and delivery of irinotecan in a rat model using a clinical transcranial MRI-guided focused ultrasound system. Scientific Reports 10:1.
Crossref
Crossref
Qimeihui Wang, Guoqing Sui, Xiaoli Wu, Dengke Teng, Lingyu Zhu, Shihui Guan, Haitao Ran, Zhigang Wang & Hui Wang. (2020) A sequential targeting nanoplatform for anaplastic thyroid carcinoma theranostics. Acta Biomaterialia 102, pages 367-383.
Crossref
Crossref
A. F. Cardona, L. Rojas, B. Wills, A. Ruiz-Patiño, L. Abril, F. Hakim, E. Jiménez, N. Useche, S. Bermúdez, J. A. Mejía, J. F. Ramón, H. Carranza, C. Vargas, J. Otero, P. Archila, J. Rodríguez, J. Rodríguez, J. Behaine, D. González, J. Jacobo, H. Cifuentes, O. Feo, P. Penagos, D. Pineda, L. Ricaurte, L. E. Pino, C. Vargas, J. C. Marquez, M. I. Mantilla, L. D. Ortiz, C. Balaña, R. Rosell, Z. L. Zatarain-Barrón & O. Arrieta. (2019) A comprehensive analysis of factors related to carmustine/bevacizumab response in recurrent glioblastoma. Clinical and Translational Oncology 21:10, pages 1364-1373.
Crossref
Crossref
Anupriya Anand, Abimanyu Sugumaran & Damodharan Narayanasamy. (2019) Brain targeted delivery of anticancer drugs: prospective approach using solid lipid nanoparticles. IET Nanobiotechnology 13:4, pages 353-362.
Crossref
Crossref
Nataliya Zhukova, Revathi Rajagopal, Adrienne Lam, Lee Coleman, Peter Shipman, Thomas Walwyn, Molly Williams, Michael Sullivan, Martin Campbell, Kanika Bhatia, Nicholas G. Gottardo & Jordan R. Hansford. (2019) Use of bevacizumab as a single agent or in adjunct with traditional chemotherapy regimens in children with unresectable or progressive low-grade glioma. Cancer Medicine 8:1, pages 40-50.
Crossref
Crossref
J. N. Jakobsen, T. Urup, K. Grunnet, A. Toft, M. D. Johansen, S. H. Poulsen, I. J. Christensen, A. Muhic & H. S. Poulsen. (2018) Toxicity and efficacy of lomustine and bevacizumab in recurrent glioblastoma patients. Journal of Neuro-Oncology 137:2, pages 439-446.
Crossref
Crossref
Ok-Sun KimJang Woo ParkEun Sang LeeRan Ji YooWon-Il KimKyo Chul LeeJae Hoon ShimHye Kyung Chung. (2018)
[
18
F]FET PET is a useful tool for treatment evaluation and prognosis prediction of anti-angiogenic drug in an orthotopic glioblastoma mouse model
. Laboratory Animal Research 34:4, pages 248.
Crossref
Crossref
Rongrong Zhu, Zhaoqi Wang, Peng Liang, Xiaolie He, Xizhen Zhuang, Ruiqi Huang, Mei Wang, Qigang Wang, Yechang Qian & Shilong Wang. (2017) Efficient VEGF targeting delivery of DOX using Bevacizumab conjugated SiO2@LDH for anti-neuroblastoma therapy. Acta Biomaterialia 63, pages 163-180.
Crossref
Crossref
Giuseppe Lombardi, Ardi Pambuku, Luisa Bellu, Miriam Farina, Alessandro Della Puppa, Luca Denaro & Vittorina Zagonel. (2017) Effectiveness of antiangiogenic drugs in glioblastoma patients: A systematic review and meta-analysis of randomized clinical trials. Critical Reviews in Oncology/Hematology 111, pages 94-102.
Crossref
Crossref
Yuping Li, Mengzhuo Hou, Guangyu Lu, Natalia Ciccone, Xingdong Wang & Hengzhu Zhang. (2016) The Prognosis of Anti-Angiogenesis Treatments Combined with Standard Therapy for Newly Diagnosed Glioblastoma: A Meta-Analysis of Randomized Controlled Trials. PLOS ONE 11:12, pages e0168264.
Crossref
Crossref
Luigi Battaglia, Marina Gallarate, Elena Peira, Daniela Chirio, Ilaria Solazzi, Susanna Marzia Adele Giordano, Casimiro Luca Gigliotti, Chiara Riganti & Chiara Dianzani. (2015)
Bevacizumab loaded solid lipid nanoparticles prepared by the coacervation technique: preliminary
in vitro
studies
. Nanotechnology 26:25, pages 255102.
Crossref
Crossref
R. Rahman, K. Hempfling, A. D. Norden, D. A. Reardon, L. Nayak, M. L. Rinne, R. Beroukhim, L. Doherty, S. Ruland, A. Rai, J. Rifenburg, D. LaFrankie, B. M. Alexander, R. Y. Huang, P. Y. Wen & E. Q. Lee. (2014) Retrospective study of carmustine or lomustine with bevacizumab in recurrent glioblastoma patients who have failed prior bevacizumab. Neuro-Oncology 16:11, pages 1523-1529.
Crossref
Crossref
Kelong Han, Jin Jin, Mauricio Maia, John Lowe, Martina A. Sersch & David E. Allison. (2014) Lower Exposure and Faster Clearance of Bevacizumab in Gastric Cancer and the Impact of Patient Variables: Analysis of Individual Data from AVAGAST Phase III Trial. The AAPS Journal 16:5, pages 1056-1063.
Crossref
Crossref
Raymond Y. Huang, Rifaquat Rahman, Alhafidz Hamdan, Caroline Kane, Christina Chen, Andrew D. Norden, David A. Reardon, Srinivasan Mukundun & Patrick Y. Wen. (2013) Recurrent glioblastoma: Volumetric assessment and stratification of patient survival with early posttreatment magnetic resonance imaging in patients treated with bevacizumab. Cancer 119:19, pages 3479-3488.
Crossref
Crossref
Linda Sooman, Simon Ekman, Claes Andersson, Hanna Göransson Kultima, Anders Isaksson, Fredrik Johansson, Michael Bergqvist, Erik Blomquist, Johan Lennartsson & Joachim Gullbo. (2013) Synergistic interactions between camptothecin and EGFR or RAC1 inhibitors and between imatinib and Notch signaling or RAC1 inhibitors in glioblastoma cell lines. Cancer Chemotherapy and Pharmacology 72:2, pages 329-340.
Crossref
Crossref
J. L. Boxerman, Z. Zhang, Y. Safriel, M. Larvie, B. S. Snyder, R. Jain, T. L. Chi, A. G. Sorensen, M. R. Gilbert & D. P. Barboriak. (2013) Early post-bevacizumab progression on contrast-enhanced MRI as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 Central Reader Study. Neuro-Oncology 15:7, pages 945-954.
Crossref
Crossref
E.-M. Ratai, Z. Zhang, B. S. Snyder, J. L. Boxerman, Y. Safriel, R. C. McKinstry, F. Bokstein, M. R. Gilbert, A. G. Sorensen & D. P. Barboriak. (2013) Magnetic resonance spectroscopy as an early indicator of response to anti-angiogenic therapy in patients with recurrent glioblastoma: RTOG 0625/ACRIN 6677. Neuro-Oncology 15:7, pages 936-944.
Crossref
Crossref
J.-M. Escoffre, A. Novell, S. Serrière, T. Lecomte & A. Bouakaz. (2013)
Irinotecan Delivery by Microbubble-Assisted Ultrasound:
In Vitro
Validation and a Pilot Preclinical Study
. Molecular Pharmaceutics 10:7, pages 2667-2675.
Crossref
Crossref
Yongzhi Wang & Tao Jiang. (2013) Understanding high grade glioma: Molecular mechanism, therapy and comprehensive management. Cancer Letters 331:2, pages 139-146.
Crossref
Crossref
Iben Kümler, Nils Brünner, Jan Stenvang, Eva Balslev & Dorte L. Nielsen. (2013) A systematic review on topoisomerase 1 inhibition in the treatment of metastatic breast cancer. Breast Cancer Research and Treatment 138:2, pages 347-358.
Crossref
Crossref
Jing Li, Manish Gupta, Denise Jin, Yan Xin, Jennifer Visich & David E. Allison. (2012) Characterization of the long-term pharmacokinetics of bevacizumab following last dose in patients with resected stage II and III carcinoma of the colon. Cancer Chemotherapy and Pharmacology 71:3, pages 575-580.
Crossref
Crossref
Aurélien Corroyer-Dulmont, Elodie A. Pérès, Edwige Petit, Jean-Sébastien Guillamo, Nathalie Varoqueaux, Simon Roussel, Jérôme Toutain, Didier Divoux, Eric T. MacKenzie, Jérôme Delamare, Méziane Ibazizène, Myriam Lecocq, Andréas H. Jacobs, Louisa Barré, Myriam Bernaudin & Samuel Valable. (2013) Detection of glioblastoma response to temozolomide combined with bevacizumab based on µMRI and µPET imaging reveals [18F]-fluoro-l-thymidine as an early and robust predictive marker for treatment efficacy. Neuro-Oncology 15:1, pages 41-56.
Crossref
Crossref
Aida Muhic, Hans Skovgaard Poulsen, Morten Sorensen, Kirsten Grunnet & Ulrik Lassen. (2012) Phase II open-label study of nintedanib in patients with recurrent glioblastoma multiforme. Journal of Neuro-Oncology 111:2, pages 205-212.
Crossref
Crossref
Guobin Zhang, Shengyue Huang & Zhongcheng Wang. (2012) A meta-analysis of bevacizumab alone and in combination with irinotecan in the treatment of patients with recurrent glioblastoma multiforme. Journal of Clinical Neuroscience 19:12, pages 1636-1640.
Crossref
Crossref
Hana Yu, Junseong Park, Jungsul Lee, Kyungsun Choi & Chulhee Choi. (2012) Constitutive Expression of MAP Kinase Phosphatase-1 Confers Multi-drug Resistance in Human Glioblastoma Cells. Cancer Research and Treatment 44:3, pages 195-201.
Crossref
Crossref